Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)

INTRODUCTION: An extrafine formulation of the long-acting muscarinic antagonist, glycopyrronium bromide (GB), has been developed for delivery via the NEXThaler dry powder inhaler (DPI). This study assessed the bronchodilator efficacy and safety of different doses of this formulation in patients with...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Int J Chron Obstruct Pulmon Dis
Huvudupphovsmän: Beeh, Kai M, Emirova, Aida, Prunier, Hélène, Santoro, Debora, Nandeuil, Marie Anna
Materialtyp: Artigo
Språk:Inglês
Publicerad: Dove Medical Press 2018
Ämnen:
Clinical Trial Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5973313/
https://ncbi.nlm.nih.gov/pubmed/29872288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S168493
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk